Background Conventional cytogenetic and comparative genomic hybridization (CGH)
studies in brain malignancies have shown that glioblastoma multiforme (GBM) is …

We have used a new method of genomic microarray to investigate amplification of
oncogenes throughout the genome of glioblastoma multiforme (GBM). Array-based …

Screening the whole glioblastoma multiforme (GBM) genome for aberrations is a good
starting point when looking for molecular markers that could potentially stratify patients …

Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that allows
the genome-wide analysis of DNA sequence copy number differences. We applied …

Glioblastoma Multiforme (GBM) is a malignant brain cancer that develops after accumulating
genomic DNA damage that often includes gene amplifications and/or deletions. These copy …

Glioblastoma multiforme (GBM) is an extremely malignant brain tumor. To identify new
genomic alterations in GBM, genomic DNA of tumor tissue/explants from 55 individuals and …

Identification of genetic copy number changes in glial tumors is of importance in the context
of improved/refined diagnostic, prognostic procedures and therapeutic decision-making. In …

Background Genomic hybridization platforms, including BAC-CGH and genotyping arrays,
have been used to estimate chromosome copy number (CN) in tumor samples by detecting …

Glioblastomas are cytogenetically heterogeneous tumors that frequently display alterations
of chromosomes 7, 9p, and 10q. We used high-density (500K) single-nucleotide …

Conventional comparative genomic hybridization (CGH) profiling of neuroblastomas has
identified many genomic aberrations, although the limited resolution has precluded a …